

Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation

NCT05967052

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Enrollment	132 participants

Key Eligibility Criteria

Inclusion (8)

- The patient correctly gave written informed consent to participate in the study;
- Men or women between the ages of 18 and 65 inclusive at the time of signing the informed consent;
- Patient after a minimum of 6 months from the documented detection of SARS-CoV-2 infection (document confirming the history of the disease, including a positive result of the PCR or antigen test, certificate of convalescence; medical documentation confirming the infection; the condition is also considered fulfilled in the case of documented infection asymptomatic);
- During the screening, the patient meets the criteria for the diagnosis of chronic fatigue syndrome (CFS) according to the National Academy of Medicine (2015);
- Women:
... and 3 more (see full listing online)

Exclusion (5)

- Vital functions disorders;
- Documented hypersensitivity to pregabalin or any of the excipients of the formulation (i.e., lactose);
- Moderate or severe depression during treatment or present during psychiatric evaluation at baseline;
- Concurrent treatment with opioids or other antiepileptic drugs (including tramadol, buprenorphine, morphine, oxycodone, gabapentin, duloxetine);
- Pregnant or breastfeeding women.

Locations (1 total)

Centrum Wsparcia BadaD Klinicznych, Warsaw, Masovian Voivodeship, Poland